谭桐,朱恩军,崔颢,来永强

• 1:首都医科大学附属北京安贞医院心脏外科中心北京市心肺血管疾病研究所

摘要(Abstract)：

经导管主动脉瓣置换术（TAVR）在低危和低龄患者中的应用日益增加。然而，这一趋势要求心外科医师承担起更为复杂的全生命周期管理的重任。本文探讨了3个全生命周期管理的重点，包括第1枚瓣膜的选择、TAVR的手术成功率与器械成功率以及瓣膜耐久性。TAVR患者年轻化，需考虑其全生命周期管理的复杂性，包括可能的二次手术风险。提高TAVR的手术成功率与器械成功率，是全生命周期管理的基石，需在手术策略和操作层面努力降低并发症的发生。瓣膜耐久性是全生命周期管理的保障，目前的外科生物瓣膜耐久性良好，但TAVR瓣膜的长期耐久性数据仍需进一步积累。同时，新型瓣膜在耐久性方面不断改良，为优化TAVR患者的全生命周期管理提供了新方向。

关键词(KeyWords)： 经导管主动脉瓣置换术;外科主动脉瓣置换术;介入治疗;全生命周期管理;瓣膜耐久性

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金优秀青年基金项目;; 首都医科大学优秀青年项目（KCA2305）;; 首都医学科学创新中心项目（CX23YQA05）;; 北京安贞医院国家心血管疾病临床医学研究中心高水平研究专项项目（2024AZC1003）;; 北京市自然科学基金项目（7222042）

作者(Author): 谭桐,朱恩军,崔颢,来永强

参考文献(References)：

• [1] Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT registry of transcatheter aortic valve replacement[J]. J Am Coll Cardiol, 2020, 76(21):2492-2516. DOI:10.1016/j.jacc.2020.09.595.
• [2] Graversen PL, Butt JH，?stergaard L, et al. Changes in aortic valve replacement procedures in Denmark from 2008 to 2020[J]. Heart, 2023, 109(7):557-563. DOI:10.1136/heartjnl-2022-321594.
• [3]潘文志，方雁行，李捷，等.经导管主动脉瓣置换术2023年度报告[J].中国胸心血管外科临床杂志，2024, 31(4):498-503. DOI:10.7507/1007-4848.202401070.
• [4] Mack MJ,Leon MB,Thourani VH, et al. Transcatheter aorticvalve replacement in low-risk patients at five years[J]. N Engl J Med,2023,389(21):1949-1960. DOI:10.1056/NEJMoa2307447.
• [5] Blankenberg S,Seiffert M,Vonthein R,et al. Transcatheter or surgical treatment of aortic-valve stenosis[J]. N Engl J Med,2024,390(17):1572-1583. DOI:10.1056/NEJMoa2400685.
• [6] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2021, 77(4):450-500. DOI:10.1016/j.jacc.2020.11.035.
• [7]国家心血管病中心，国家结构性心脏病介入质控中心，中华医学会心血管病学分会，等.经导管主动脉瓣置换术临床实践指南[J].中华医学杂志，2023,103(12):886-900.DOI:10.3760/cma.j.cn112137-20221106-02332.
• [8] Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aorticvalve replacement in low-risk patients at fi ve years[J]. N Engl J Med, 2023, 389(21):1949-1960. DOI:10.1056/NEJMoa2307447.
• [9] Lim GB. Suitability of TAVI in low-risk patients[J]. Nat Rev Cardiol, 2023, 20(5):284. DOI:10.1038/s41569-023-00862-6.
• [10] Thyregod HGH, J?rgensen TH, Ihlemann N, et a l. Transcatheter or surgical aortic valve implantation:10-year outcomes of the NOTION trial[J]. Eur Heart J, 2024, 45(13):1116-1124. DOI:10.1093/eurheartj/ehae043.
• [11] Gupta T, DeVries JT, Gilani F, et al. Temporal trends i n transcatheter aortic valve replacement for isolated severe aortic stenosis[J]. J Soc Cardiovasc Angiogr Interv,2024,3(7):101861. DOI:10.1016/j.jscai.2024.101861.
• [12] Windecker S, Okuno T, Unbehaun A, et al. Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?[J]. Eur Heart J, 2022,43(29):2729-2750. DOI:10.1093/eurheartj/ehac105.
• [13] Fukuhara S, Brescia AA, Deeb GM. Surgical explantation of transcatheter aortic bioprostheses:an analysis from the society of thoracic surgeons database[J]. Circulation,2 0 2 0, 1 4 2(2 3):2 2 8 5-2 2 8 7. D O I:1 0. 1 1 6 1/CIRCULATIONAHA.120.050499.
• [14] SáMP, Jacquemyn X, Van den Eynde J, et al. Impact of paravalvular leak on outcomes after transcatheter aortic valve implantation:meta-analysis of kaplan-meier-derived individual patient data[J]. Struct Heart, 2022, 7(2):100118.DOI:10.1016/j.shj.2022.100118.
• [15] Okuno T, Tomii D, Heg D, et al. Five-year outcomes of mild paravalvular regurgitation after transcatheter aortic valve implantation[J]. EuroIntervention, 2022, 18(1):33-42.DOI:10.4244/EIJ-D-21-00784.
• [16]潘欣，李艳杰，何奔.主动脉瓣置换术后瓣周漏的重新认识和应对[J].中华心血管病杂志，2023, 51(7):696-701.DOI:10.3760/cma.j.cn112148-20230531-00319.
• [17] Sammour Y, Krishnaswamy A, Kumar A, et al. Incidence,predictors, and implications of permanent pacemaker requirement after transcatheter aortic valve replacement[J].JACC Cardiovasc Interv, 2021, 14(2):115-134. DOI:10.1016/j.jcin.2020.09.063.
• [18] Yu Q, Fu Q, Xia Y, et al. Predictors, clinical impact,and management strategies for conduction abnormalities after transcatheter aortic valve replacement:an updated review[J].Front Cardiovasc Med, 2024, 11:1370244. DOI:10.3389/fcvm.2024.1370244.
• [19] SáMP, Jacquemyn X, Sun T, et al. Late outcomes of permanent pacemaker implantation after TAVR:meta-analysis of reconstructed time-to-event data[J]. J Soc Cardiovasc Angiogr Interv, 2022, 1(5):100434. DOI:10.1016/j.jscai.2022.100434.
• [20] Lazar HL. Management of coronary artery obstruction following TAVR-The importance of the heart team approach[J]. J Card Surg,2017,32(12):782. DOI:10.1111/jocs.13247.
• [21] Shinn SH, Altarabsheh SE, Deo SV, et al. A systemic review and meta-analysis of sutureless aortic valve replacement versus transcatheter aortic valve implantation[J]. Ann Thorac Surg, 2018, 106(3):924-929. DOI:10.1016/j.athoracsur.2018.03.059.
• [22] Tan T, Wei P, Liu Y, et al. Safety and efficacy of two-port thoracoscopic aortic valve replacement[J]. J Cardiothorac Surg, 2023, 18(1):9. DOI:10.1186/s13019-022-02086-0.
• [23] Fatima B, Mohananey D, Khan FW, et al. Durability data for bioprosthetic surgical aortic valve:a systematic review[J].JAMA Cardiol, 2019, 4(1):71-80. DOI:10.1001/jamacardio.2018.4045.
• [24] Singh SK, Kachel M, Castillero E, et al. Polymeric prosthetic heart valves:a review of current technologies and future directions[J]. Front Cardiovasc Med, 2023, 10:1137827.DOI:10.3389/fcvm.2023.1137827.